|Articles|September 1, 2001
PDT offers good response, recurrence rates for multiple BCCs
Of 106 lesions, all healed with good cosmetic results and only three lesions had recurrences
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.